Monday, January 18, 2021
Home Latest Pharma-News Astellas and Welldoc together develop and commercialize BlueStar® a digital health...

Astellas and Welldoc together develop and commercialize BlueStar® a digital health solution cleared by the U.S. Food and Drug Administration (FDA) for the treatment of type 1 or type 2 diabetes

Nov 20, 2019  – Astellas Pharma Inc. and Welldoc, Inc. announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions, BlueStar® in Japan and certain other Asian markets for patients with diabetes.

U.S. Food and Drug Administration (FDA)- in the United States cleared the use of BlueStar  by healthcare providers and their patients aged 18 years and older who have type 1 or  type 2 diabetes. It not only assists patients in managing their disease by capturing ,transmitting blood glucose data and tracking medication, activity, diet and exercise, but also useful for  individual patient treatment data and machine learning to provide customized motivational, behavioral, and educational training messages to aid in diabetes self-management. https://www.astellas.com/en/news/15441

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

thirteen + twelve =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...